Choose a language and wait for the translated text.
Shots:
Astex has entered into an exclusive, worldwide research collaboration & license agreement with Genentech to identify small molecules with selective inhibitory activity for the treatment for breast cancer
Astex will license compounds from its breast cancer discovery program to Genentech and jointly optimize lead compounds through preclinical candidate selection, after which Genentech will lead global development & commercialization
Astex will receive $25M upfront & is eligible for over $490M in preclinical, clinical, regulatory, & sales milestones, plus tiered royalties on net sales of medicines arising from the collaboration
Ref: Globenewswire | Image: Genentech & Astex | Press Release
Related News: Genentech Reports the US FDA’s sBLA Acceptance of Lunsumio VELO + Polivy for R/R Large B-Cell Lymphoma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Astex Pharmaceuticals Partners with Genentech for Breast Cancer Therapy Program in a Deal Worth Over $515M appeared first on PharmaShots.
